[
    "{\"step_by_step_thinking\": \"The documents mention that CAR-T cell therapies have been approved for the treatment of B cell malignancies. For example, Document [1] mentions that there are currently three FDA-approved products for the treatment of relapsed/refractory large B-cell lymphoma and pediatric B-cell acute lymphocytic leukemia. Document [2] also mentions that CAR-T cells have two FDA-approved indications including relapsed or refractory acute lymphoblastic leukemia in children and young adults as well as large B cell lymphoma that is relapsed and/or refractory to two prior therapies.\", \"answer_choice\": \"A\"}"
]